A Model-Based Economic Evaluation of Hypothetical Treatments for Amyotrophic Lateral Sclerosis in the UK: Implications for Pricing of New and Emerging Health Technologies.

MLA

Tappenden, Paul, et al. “A Model-Based Economic Evaluation of Hypothetical Treatments for Amyotrophic Lateral Sclerosis in the UK: Implications for Pricing of New and Emerging Health Technologies.” PharmacoEconomics, vol. 42, no. 9, Sept. 2024, pp. 1003–16. EBSCOhost, https://doi.org/10.1007/s40273-024-01395-7.

APA

Tappenden, P., Hardiman, O., Kwon, S.-H., Mon-Yee, M., Galvin, M., & McDermott, C. (2024). A Model-Based Economic Evaluation of Hypothetical Treatments for Amyotrophic Lateral Sclerosis in the UK: Implications for Pricing of New and Emerging Health Technologies. PharmacoEconomics, 42(9), 1003–1016. https://doi.org/10.1007/s40273-024-01395-7

Chicago

Tappenden, Paul, Orla Hardiman, Sun-Hong Kwon, Mon Mon-Yee, Miriam Galvin, and Christopher McDermott. 2024. “A Model-Based Economic Evaluation of Hypothetical Treatments for Amyotrophic Lateral Sclerosis in the UK: Implications for Pricing of New and Emerging Health Technologies.” PharmacoEconomics 42 (9): 1003–16. doi:10.1007/s40273-024-01395-7.